525 related articles for article (PubMed ID: 26553194)
1. Adverse cutaneous drug eruptions: current understanding.
Hoetzenecker W; Nägeli M; Mehra ET; Jensen AN; Saulite I; Schmid-Grendelmeier P; Guenova E; Cozzio A; French LE
Semin Immunopathol; 2016 Jan; 38(1):75-86. PubMed ID: 26553194
[TBL] [Abstract][Full Text] [Related]
2. Treatments for Severe Cutaneous Adverse Reactions.
Cho YT; Chu CY
J Immunol Res; 2017; 2017():1503709. PubMed ID: 29445753
[TBL] [Abstract][Full Text] [Related]
3. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).
Owen CE; Jones JM
Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239
[TBL] [Abstract][Full Text] [Related]
4. Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.
Coleman I; Ruiz G; Brahmbhatt S; Ackerman L
J Med Case Rep; 2020 Nov; 14(1):210. PubMed ID: 33138853
[TBL] [Abstract][Full Text] [Related]
5. Outpatient management and follow-up recommendations for adverse drug reactions: guidelines for posthospitalization care.
Khanna R; Vaudreuil A; Lake E
Cutis; 2019 May; 103(5):254-256;258. PubMed ID: 31233575
[TBL] [Abstract][Full Text] [Related]
6. [The major SCAR syndromes].
Piérard GE; Lesuisse M; Piérard-Franchimont C
Rev Med Liege; 2017 Oct; 72(10):444-447. PubMed ID: 29058836
[TBL] [Abstract][Full Text] [Related]
7. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.
Godfrey H; Jedlowski P; Thiede R
Australas J Dermatol; 2024 May; 65(3):243-253. PubMed ID: 38572842
[TBL] [Abstract][Full Text] [Related]
8. [Identification of cutaneous adverse drug reactions].
Ingen-Housz-Oro S
Rev Prat; 2023 Mar; 73(3):307-313. PubMed ID: 37289124
[TBL] [Abstract][Full Text] [Related]
9. Severe cutaneous adverse reactions related to systemic antibiotics.
Lin YF; Yang CH; Sindy H; Lin JY; Rosaline Hui CY; Tsai YC; Wu TS; Huang CT; Kao KC; Hu HC; Chiu CH; Hung SI; Chung WH
Clin Infect Dis; 2014 May; 58(10):1377-85. PubMed ID: 24599767
[TBL] [Abstract][Full Text] [Related]
10. Severe acute generalized exanthematous pustulosis with blistering mimicking toxic epidermal necrolysis, associated with a primary mumps infection.
Azib S; Florin V; Fourrier F; Delaporte E; Staumont-Sallé D
Clin Exp Dermatol; 2014 Aug; 39(6):723-5. PubMed ID: 24986490
[TBL] [Abstract][Full Text] [Related]
11. Severe cutaneous adverse reactions.
Hung SI; Mockenhaupt M; Blumenthal KG; Abe R; Ueta M; Ingen-Housz-Oro S; Phillips EJ; Chung WH
Nat Rev Dis Primers; 2024 Apr; 10(1):30. PubMed ID: 38664435
[TBL] [Abstract][Full Text] [Related]
12. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J;
Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927
[TBL] [Abstract][Full Text] [Related]
13. Systemic drug reactions with skin involvement: Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS.
Darlenski R; Kazandjieva J; Tsankov N
Clin Dermatol; 2015; 33(5):538-41. PubMed ID: 26321400
[TBL] [Abstract][Full Text] [Related]
14. Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.
Mustafa SS; Ostrov D; Yerly D
Curr Allergy Asthma Rep; 2018 Mar; 18(4):26. PubMed ID: 29574562
[TBL] [Abstract][Full Text] [Related]
15. Acute generalized exanthematous pustulosis: analysis of cases managed in a tertiary hospital in Singapore.
Lee HY; Chou D; Pang SM; Thirumoorthy T
Int J Dermatol; 2010 May; 49(5):507-12. PubMed ID: 20534083
[TBL] [Abstract][Full Text] [Related]
16. Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9-year experience in a tertiary care paediatric hospital setting.
Liccioli G; Mori F; Parronchi P; Capone M; Fili L; Barni S; Sarti L; Giovannini M; Resti M; Novembre EM
Clin Exp Allergy; 2020 Jan; 50(1):61-73. PubMed ID: 31608511
[TBL] [Abstract][Full Text] [Related]
17. Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China.
Deng M; Su Y; Wu R; Li S; Tang G; Kuang Q; Luo X; Zhu Y; Shen W
Int Immunopharmacol; 2023 Jan; 114():109530. PubMed ID: 36508915
[TBL] [Abstract][Full Text] [Related]
18. Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis.
Hadavand MA; Kaffenberger B; Cartron AM; Trinidad JCL
J Am Acad Dermatol; 2022 Sep; 87(3):632-639. PubMed ID: 32926975
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous adverse drug reactions: Kids are not just little people.
Waldman R; Whitaker-Worth D; Grant-Kels JM
Clin Dermatol; 2017; 35(6):566-582. PubMed ID: 29191348
[TBL] [Abstract][Full Text] [Related]
20. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome.
Harr T; French LE
Med Clin North Am; 2010 Jul; 94(4):727-42, x. PubMed ID: 20609860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]